HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barone, R. Articles by Pauwels, S. Search for Related Content PubMed PubMed Citation Articles by Barone, R. Articles by Pauwels, S.

Patient-Specific Dosimetry in Predicting Renal Toxicity with ⁹⁰Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose–Effect Relationship

¹ Centre of Nuclear Medicine and Laboratory of Positron Emission Tomography; Université Catholique de Louvain, Brussels and Louvain-la-Neuve, Belgium
² Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
³ Department of Biostatistics, Centre Léon Bérard, Lyon, France
⁴ H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida

Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog ⁹⁰Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-D-Phe¹-Tyr³-octreotide (DOTATOC). Pretherapeutic assessment of kidney absorbed dose could help to minimize the risk of renal toxicity. The aim of this study was to evaluate the contribution of patient-specific adjustments to the standard dosimetric models, such as the renal volume and dose rate, for estimating renal absorbed dose during therapy with ⁹⁰Y-DOTATOC. In particular, we investigated the correlation between dose estimates and effect on renal function after therapy. Methods: Eighteen patients with neuroendocrine tumors (9 men and 9 women; median age, 59 y) underwent treatment with ⁹⁰Y-DOTATOC (8.1–22.9 GBq) after pretherapeutic biodistribution study with ⁸⁶Y-DOTATOC. Kidney uptake and residence times were measured and the absorbed dose (KAD) was computed using either the MIRDOSE3.1 software assuming a standard kidney volume (KAD_StdVol) or the MIRD Pamphlet 19 values and the actual kidney cortex volume determined by pretherapeutic CT (KAD_CTVol). For each patient, the biologic effective dose (BED) was calculated according to the linear quadratic model to take into account the effect of dose rate and fractionation. Renal function was evaluated every 6 mo by serum creatinine and creatinine clearance (CLR) during a median follow-up of 35.5 mo (range, 18–65 mo). The individual rate of decline of renal function was expressed as CLR loss per year. Results: KAD_CTVol ranged between 19.4 and 39.6 Gy (mean, 28.9 ± 5.34 Gy). BED, obtained from KAD_CTVol, ranged between 27.7 and 59.3 Gy (mean, 40.4 ± 10.6 Gy). The CLR loss per year ranged from 0% to 56.4%. In 12 of 18 patients, CLR loss per year was <20%. No correlation was observed between CLR loss per year and the KAD_StdVol or the KAD_CTVol. In contrast, BED strongly correlated with CLR loss per year (r = 0.93; P < 0.0001). All 5 patients with CLR loss per year >20% received a BED >45 Gy. Patients who were treated with low fractionation were those with the highest rate of renal function impairment. Conclusion: Radiation nephrotoxicity after ⁹⁰Y-DOTATOC therapy is dose dependent. Individual renal volume, dose rate, and fractionation play important roles in an accurate dosimetry estimation that enables prediction of risk of renal function impairment.

Key Words: kidney dosimetry • ⁹⁰Y-DOTA-Tyr³-octreotide • radionuclide therapy • radiation nephropathy

This article has been cited by other articles:

				H. Karacay, R. M. Sharkey, D. V. Gold, D. R. Ragland, W. J. McBride, E. A. Rossi, C.-H. Chang, and D. M. Goldenberg Pretargeted Radioimmunotherapy of Pancreatic Cancer Xenografts: TF10-90Y-IMP-288 Alone and Combined with Gemcitabine J. Nucl. Med., December 1, 2009; 50(12): 2008 - 2016. [Abstract] [Full Text] [PDF]

				S. Samnick, B. F. Romeike, T. Lehmann, I. Israel, C. Rube, A. Mautes, C. Reiners, and C.-M. Kirsch Efficacy of Systemic Radionuclide Therapy with p-131I-Iodo-L-Phenylalanine Combined with External Beam Photon Irradiation in Treating Malignant Gliomas J. Nucl. Med., December 1, 2009; 50(12): 2025 - 2032. [Abstract] [Full Text] [PDF]

				L. Devizzi, A. Guidetti, C. Tarella, M. Magni, P. Matteucci, E. Seregni, C. Chiesa, E. Bombardieri, M. Di Nicola, C. Carlo-Stella, et al. High-Dose Yttrium-90-Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation J. Clin. Oncol., November 10, 2008; 26(32): 5175 - 5182. [Abstract] [Full Text] [PDF]

				B. W. Wessels, M. W. Konijnenberg, R. G. Dale, H. B. Breitz, M. Cremonesi, R. F. Meredith, A. J. Green, L. G. Bouchet, A. B. Brill, W. E. Bolch, et al. MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy J. Nucl. Med., November 1, 2008; 49(11): 1884 - 1899. [Abstract] [Full Text] [PDF]

				M. Cremonesi, M. Ferrari, C. M. Grana, A. Vanazzi, M. Stabin, M. Bartolomei, S. Papi, G. Prisco, G. Martinelli, G. Paganelli, et al. High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment J. Nucl. Med., November 1, 2007; 48(11): 1871 - 1879. [Abstract] [Full Text] [PDF]

				M. Lassmann and H. Hanscheid Spatial Dose Mapping for Individualizing Radioiodine Treatment J. Nucl. Med., January 1, 2007; 48(1): 2 - 4. [Full Text] [PDF]

				M. Konijnenberg, M. Melis, R. Valkema, E. Krenning, and M. de Jong Radiation Dose Distribution in Human Kidneys by Octreotides in Peptide Receptor Radionuclide Therapy J. Nucl. Med., January 1, 2007; 48(1): 134 - 142. [Abstract] [Full Text] [PDF]

				M. Cremonesi, M. Ferrari, L. Bodei, G. Tosi, and G. Paganelli Dosimetry in Peptide Radionuclide Receptor Therapy: A Review J. Nucl. Med., September 1, 2006; 47(9): 1467 - 1475. [Abstract] [Full Text] [PDF]

				G A Kaltsas, D Papadogias, P Makras, and A B Grossman Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699. [Abstract] [Full Text] [PDF]